Market Outlook

By 2035, the U.S. Point-of-Care Diagnostics Devices Market is expected to reach approximately USD 42.50 billion, expanding at a CAGR of approximately 9.60% during 2026–2035. The market is estimated at USD 16.99 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions. The historical market is estimated to have expanded from approximately USD 11.78 billion in 2021 to USD 15.50 billion in 2024, reflecting the structural shift of diagnostic testing from centralized laboratories toward emergency departments, physician offices, urgent care centers, pharmacies, outpatient facilities and patient homes. The 2025 and 2035 market anchors are consistent with a recent U.S. market assessment that places the market at USD 16.99 billion in 2025 and approximately USD 42.5 billion by 2035.

Point-of-care diagnostics has moved beyond being a convenience-driven testing category. It is becoming a strategic component of U.S. clinical workflow design because diagnostic turnaround time increasingly influences treatment initiation, patient disposition, antibiotic stewardship, emergency department throughput, chronic disease management and patient satisfaction. Hospitals and ambulatory providers are therefore evaluating POC technologies not simply on analyzer price, but on total cost per reported result, labor requirements, repeat-testing rates, time-to-clinical-decision, CLIA complexity, interoperability, quality-control burden and reimbursement suitability.

Demand is supported by the scale of the U.S. healthcare delivery system. The country has approximately 6,100 hospitals, more than 907,000 staffed hospital beds and around 35.7 million annual hospital admissions, creating a substantial installed base for bedside glucose testing, blood gases, cardiac markers, coagulation, molecular respiratory testing and other near-patient diagnostic workflows. Outside hospitals, decentralized testing is being strengthened by physician-office laboratories, urgent care networks, retail clinics, pharmacies and home-testing models.

The strongest value expansion through 2035 is expected to come from multiplex molecular infectious-disease testing, digitally connected glucose and cardiometabolic testing, rapid cardiac and critical-care biomarkers, CLIA-waived molecular platforms, microfluidic systems, high-sensitivity biosensors and consumer-directed diagnostics that can transfer usable results into clinician workflows. The commercial advantage will increasingly shift from single-test products toward platforms capable of supporting broader menus, faster result interpretation, electronic quality management and recurring consumable revenue.

 

Introduction

According to the U.S. Point-of-Care Diagnostics Devices Market Report, point-of-care diagnostics encompasses tests performed at or near the location where clinical decisions are made, rather than requiring specimens to travel through conventional central laboratory workflows. The market includes portable and benchtop analyzers, handheld meters, lateral-flow readers, molecular platforms, disposable cartridges, test strips, biosensor-based devices and selected self-testing systems used across acute care, primary care, ambulatory and home environments.

The U.S. market is attractive because it combines high diagnostic utilization with persistent pressure to make healthcare delivery faster and less labor intensive. Point-of-care diagnostics can shorten the interval between specimen collection and therapeutic decision-making from hours or days to minutes. This capability is particularly valuable in emergency medicine, respiratory disease, diabetes management, anticoagulation, acute cardiac care, pregnancy assessment, infectious-disease triage and settings where patients may otherwise be lost to follow-up.

Regulatory structure is also central to market development. Under CLIA, diagnostic tests are categorized as waived, moderate complexity or high complexity. Tests cleared or approved for home or over-the-counter use are generally automatically categorized as waived, while manufacturers may seek CLIA waiver for eligible moderate-complexity tests. The commercial importance of waiver status is substantial because it expands the number and type of sites capable of operating a diagnostic platform. CMS projected approximately 326,247 CLIA laboratories for FY2024, with waived laboratories representing the large majority, and CMS data indicate that about 81% of non-exempt CLIA laboratories were waiver laboratories.

The strategic direction of the market is consequently clear: diagnostics are migrating closer to the patient, while analytical capabilities traditionally associated with laboratories are being engineered into simpler, smaller and increasingly automated platforms. The winners will be manufacturers that can combine analytical quality with operational simplicity.

 

Key Market Drivers: What’s Fueling the U.S. Point-of-Care Diagnostics Devices Market Boom?

The first major market driver is the enormous U.S. chronic disease population. Diabetes is particularly important because it generates recurring testing demand across home care, outpatient medicine, emergency departments and inpatient settings. Approximately 38 million U.S. adults have diabetes, with a meaningful proportion unaware of their disease status. This creates sustained demand for glucose measurement, HbA1c testing and related cardiometabolic diagnostics.

A second driver is the continuing decentralization of care. Patients increasingly receive treatment through urgent care centers, ambulatory facilities, physician offices and retail-access models rather than solely through hospitals. These settings require tests that fit relatively small footprints, require limited technical expertise and produce actionable results before patients leave the facility. Every migration of clinical activity away from central laboratories expands the potential addressable site base for CLIA-waived POC platforms.

Infectious disease represents another powerful growth catalyst. During the 2023–2024 influenza season, the CDC estimated approximately 40 million influenza illnesses, 18 million related medical visits, 470,000 hospitalizations and 28,000 deaths in the U.S. Such seasonal respiratory burden creates an economically important demand cycle for influenza, COVID-19, RSV, strep and multiplex respiratory testing in urgent care, pediatric practices, emergency departments and physician offices.

Sexual health creates an additional decentralized testing opportunity. More than 2.4 million cases of chlamydia, gonorrhea and syphilis were reported in the U.S. during 2023, while approximately 1.2 million people were estimated to be living with HIV in 2022, including a population unaware of its status. Faster testing supports earlier treatment, linkage to care, antimicrobial stewardship and reduced patient loss between specimen collection and follow-up.

Hospital labor economics are equally important. Central laboratory staffing shortages, nursing workload, specimen transport delays and emergency department congestion increase the economic value of diagnostics that can return clinically reliable results near the patient. The purchasing argument is strongest when a POC device eliminates workflow steps rather than merely replacing one test methodology with another.

Another driver is the expansion of value-based and outcome-oriented care. Rapid identification of influenza, bacterial infections, glycemic abnormalities, coagulation status or cardiac injury can affect prescriptions, admissions, isolation decisions, imaging utilization and discharge pathways. For hospital procurement committees, the relevant financial question is therefore increasingly the downstream cost avoided per diagnostic decision.

Finally, post-pandemic consumer familiarity with self-testing has permanently enlarged the addressable market. The regulatory progression from emergency-use COVID testing toward conventional authorization of multiplex respiratory products demonstrates that at-home diagnostics are becoming a durable product class rather than an emergency-period phenomenon.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in point-of-care diagnostics is increasingly centered on molecular capability without traditional laboratory complexity. Conventional PCR historically required centralized instruments, trained technologists and batch processing. New cartridge-based and sample-to-answer systems increasingly allow molecular testing to occur in urgent care centers, emergency departments, pharmacies and physician offices.

Multiplexing is particularly important. Instead of testing sequentially for influenza, RSV, COVID-19 and other pathogens, emerging systems can evaluate several clinically similar conditions simultaneously from one specimen. bioMérieux’s CLIA-waived BIOFIRE SPOTFIRE Respiratory/Sore Throat platform, for example, can identify multiple viral and bacterial targets in approximately 15 minutes, illustrating how laboratory-grade syndromic testing is moving into decentralized care.

Miniaturization and microfluidics are another major development path. Smaller reaction volumes reduce reagent use, shorten processing time and enable portable analyzers with limited maintenance. For buyers, these improvements matter when they translate into simpler operator workflows, lower contamination risk, fewer manual pipetting steps and greater throughput per square foot.

Connectivity is becoming a major competitive differentiator. Hospitals increasingly expect POC devices to transmit results into laboratory information systems, electronic health records and middleware platforms while maintaining operator identification, quality-control documentation, lockout rules and centralized device management. For large health systems operating hundreds or thousands of bedside meters, connectivity can be as strategically important as analytical performance.

Biosensor innovation is also broadening the clinical menu. Electrochemical, optical, fluorescence and immunochemical sensing systems are enabling rapid quantification of glucose, HbA1c, cardiac biomarkers, coagulation parameters, electrolytes and other analytes. Quantitative testing offers higher clinical value than simple positive/negative results in applications where treatment intensity depends on numerical thresholds.

Manufacturers are simultaneously engineering devices specifically for CLIA waiver. Automated calibration, built-in controls, cartridge barcoding, locked workflows, guided interfaces and reduced manual preparation are not merely convenience features; they are regulatory and commercial design tools that expand addressable testing sites.

Home diagnostics represents the most visible innovation frontier. In October 2024, the FDA granted conventional marketing authorization to the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, the first OTC influenza test authorized through a traditional premarket pathway rather than solely under an emergency-use framework. The device produces results in approximately 15 minutes and established a regulatory pathway for subsequent products of the same type.

The next competitive cycle will be driven by platforms that combine molecular accuracy, consumer-level simplicity, low hands-on time, connected reporting and economically sustainable cartridges.

 

Segmentation Insights

The U.S. Point-of-Care Diagnostics Devices Market is segmented on the basis of product type, application, technology, end user and region.

 

By Product Type

Blood Glucose and Diabetes Testing Devices

Blood glucose testing remains one of the largest recurring-volume segments because diabetes management requires frequent measurements across hospitals, physician offices and patient homes. The category includes handheld glucose meters, hospital glucose systems, test strips, lancet-compatible systems, HbA1c analyzers and selected ketone-testing products.

The strategic opportunity is moving away from commodity standalone meters toward connected professional systems and HbA1c platforms that can support immediate therapy decisions. Hospitals value meters capable of centralized management and strict operator controls, while primary-care practices benefit from HbA1c results during the same patient encounter.

Infectious Disease Testing Devices

Infectious disease represents one of the fastest-growing product categories and includes respiratory antigen tests, molecular respiratory platforms, group A streptococcal testing, HIV tests, hepatitis testing, STI testing and other rapid pathogen diagnostics.

Respiratory disease is currently the primary innovation engine because influenza, COVID-19 and RSV frequently produce overlapping symptoms. This makes multiplex testing clinically and commercially attractive. Infectious disease also benefits disproportionately from CLIA waiver because urgent care centers, pediatric offices and retail-access sites need actionable diagnoses without maintaining full laboratory infrastructure.

Cardiometabolic and Cardiac Marker Devices

This segment includes cholesterol and lipid testing, troponin, BNP or NT-proBNP, CRP and related biomarkers used to support cardiovascular risk assessment and acute decision-making. POC cardiac marker testing is most valuable when laboratory turnaround materially affects emergency department triage or disposition.

Future adoption will depend on analytical sensitivity, rapid quantification and integration with clinical decision pathways. High-sensitivity biomarker capability at the point of care could expand the role of these devices in emergency and ambulatory cardiovascular workflows.

Coagulation and Critical-Care Testing Devices

Coagulation systems include PT/INR meters and other near-patient coagulation technologies used in anticoagulation clinics, hospitals and selected home settings. Critical-care devices include blood gas analyzers, electrolyte testing, lactate systems and chemistry platforms used in emergency departments, intensive care units, operating rooms and neonatal care.

These products are workflow-critical because results frequently influence immediate treatment. Procurement decisions therefore place heavy emphasis on uptime, cartridge availability, analytical comparability with the central laboratory and turnaround reliability.

Pregnancy, Fertility and Women’s Health Diagnostics

Pregnancy testing is a mature but high-volume category built around urine and blood-based rapid tests. Fertility and ovulation testing add substantial consumer demand, while molecular vaginitis and STI platforms are expanding the professional women’s-health opportunity.

The growth story is shifting from simple binary tests toward more clinically informative near-patient molecular testing. Platforms that differentiate causes of vaginal symptoms during a single patient visit can reduce empirical prescribing and repeat appointments.

Hematology, Urinalysis and Other POC Devices

This category includes compact hematology analyzers, urinalysis readers, hemoglobin testing, renal-related tests and other near-patient chemistry systems. The value proposition is strongest in sites where specimen transportation or delayed central-laboratory results can disrupt treatment.

Small physician practices, community clinics and rural facilities represent an important opportunity for multi-analyte platforms that can consolidate multiple low- to moderate-volume tests on a single instrument.

 

By Application

Infectious Disease Diagnosis

Infectious disease diagnosis is expected to remain one of the most commercially dynamic applications through 2035. The combination of seasonal respiratory disease, antimicrobial stewardship requirements and patient preference for same-visit treatment favors rapid testing.

Molecular platforms are likely to gain share over simple antigen tests when the clinical value of higher sensitivity and multiplexing justifies the higher per-test cost. Antigen tests will nevertheless remain important where affordability, simplicity and speed dominate purchasing decisions.

Diabetes and Endocrine Management

Diabetes management provides a dependable recurring-testing base because glycemic status affects medication titration, inpatient safety and long-term disease management. Professional blood glucose monitoring will remain essential in acute care, while HbA1c testing will gain strategic importance in physician offices and decentralized chronic-care programs.

The segment’s economics favor manufacturers with recurring strip or cartridge revenue and strong connectivity because the installed analyzer often functions as the gateway to long-duration consumable contracts.

Cardiovascular and Critical-Care Diagnosis

POC testing has high clinical utility in suspected myocardial infarction, heart failure, sepsis, respiratory failure, electrolyte imbalance and other acute conditions. In these situations, the economic value of rapid diagnostics is linked directly to emergency department and ICU throughput.

Buyers are likely to prefer devices that support several urgent-care analytes on one platform, reducing instrument fragmentation and training requirements.

Women’s Health, Pregnancy and Sexual Health

This application covers pregnancy testing, fertility assessment, HIV and STI diagnostics, vaginitis testing and other near-patient women’s-health applications. It is well suited to decentralized care because same-visit diagnosis can improve treatment completion and reduce follow-up loss.

Molecular sexual-health testing represents a particularly attractive growth area where clinically differentiated results can replace symptom-based treatment.

Renal, Urinary and General Screening Applications

Urinalysis, renal-related testing and general screening remain important in primary care, emergency medicine, occupational health and community settings. Although individual tests may be relatively low value, very high volumes create a durable installed market.

Automation of strip reading and electronic result capture can reduce interpretation variability and documentation errors, supporting replacement of manual workflows.

 

By Technology

Lateral Flow Assays

Lateral flow remains one of the largest POC technology categories because the format is inexpensive, portable and compatible with visual or reader-based interpretation. Pregnancy tests, respiratory antigen tests and numerous infectious-disease assays rely on this technology.

Competitive pressure is high because entry barriers are lower than in molecular diagnostics. Manufacturers increasingly differentiate through multiplex capability, digital readers, improved sensitivity and consumer-friendly packaging.

Molecular Diagnostics

Molecular diagnostics is expected to be the fastest-growing technology segment through 2035. Cartridge PCR and other nucleic-acid amplification technologies are compressing laboratory workflows into self-contained near-patient devices.

The commercial opportunity is greatest where rapid molecular results immediately change therapy. CLIA-waived molecular systems can command premium pricing because they combine laboratory-like information with decentralized accessibility.

Biosensor and Electrochemical Platforms

Biosensor technologies are foundational to glucose, blood gas, electrolyte and selected cardiometabolic testing. Their advantages include rapid signal generation, quantitative results and compatibility with small sample volumes.

Future innovation will concentrate on multi-analyte sensing, calibration stability, smaller blood requirements and digital connectivity.

Immunoassay and Fluorescence-Based Systems

POC immunoassay systems support quantitative or semi-quantitative testing for cardiac markers, infectious disease, inflammation and other biomarkers. Fluorescence readers improve analytical interpretation compared with visual-only formats and can allow one installed reader to support several assays.

This platform model generates attractive recurring consumable economics when manufacturers can expand menu breadth after analyzer placement.

Microfluidics and Other Integrated Technologies

Microfluidic platforms reduce sample and reagent volumes while integrating specimen processing, reaction and detection into compact cartridges. They are particularly important for next-generation molecular and multiplex systems.

The long-term opportunity lies in creating increasingly broad diagnostic menus on common hardware while maintaining simple sample-to-answer workflows.

 

By End User

Hospitals and Health Systems

Hospitals represent the most strategically important professional end-user group because they operate point-of-care testing across emergency departments, ICUs, operating rooms, labor and delivery, neonatal units, inpatient wards and outpatient campuses.

Large integrated delivery networks often standardize platforms at enterprise scale. Procurement committees evaluate analyzer pricing together with reagent commitments, service agreements, connectivity, middleware costs, operator training, quality-control requirements and central-laboratory governance.

Physician Offices and Urgent Care Centers

This segment is expected to gain meaningful share through 2035. Same-visit diagnosis is critical to the urgent-care operating model because patients expect rapid treatment without returning for laboratory results.

CLIA-waived respiratory, strep, glucose, HbA1c, pregnancy and molecular platforms are especially well aligned with these sites. Tests requiring only a few minutes of hands-on preparation have a competitive advantage where nursing and medical-assistant time is constrained.

Ambulatory, Emergency and Specialty Care Facilities

Ambulatory surgery centers, emergency facilities, dialysis centers, anticoagulation clinics and specialty practices require targeted POC testing tied to specific procedures. Coagulation, hemoglobin, glucose, pregnancy, blood gas and other rapid tests can reduce procedure delays and improve patient flow.

These users generally prioritize reliability and low operating complexity over broad laboratory menus.

Pharmacies, Retail Clinics and Community Testing Sites

Retail-access healthcare represents an important expansion channel for simple and CLIA-waived diagnostic systems. Pharmacies already have extensive consumer relationships and can serve as decentralized access points for selected respiratory, metabolic and infectious-disease testing.

The commercial opportunity depends heavily on state scope-of-practice rules, reimbursement pathways and the ability to link test results with clinical consultation or prescribing.

Home Care and Self-Testing

Home and self-testing is expected to be one of the fastest-growing end-user categories. COVID-19 normalized consumer use of rapid diagnostics at unprecedented scale, and manufacturers are now extending that behavior into influenza, fertility, sexual health and other applications.

The highest-value future products are likely to combine consumer usability with digital interpretation, physician connectivity and clear follow-up pathways rather than operating as isolated tests.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Point-of-Care Diagnostics Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance depends on population scale, chronic disease burden, hospital and urgent-care density, rural access, age distribution, health-system consolidation, payer mix and willingness to adopt premium decentralized technology.

Under the report’s U.S. market model, the South represents the largest regional market in 2025 at approximately USD 6.29 billion, followed by the West at USD 3.91 billion, the Northeast at USD 3.74 billion and the Midwest at USD 3.05 billion. The regional values reconcile to the national 2025 market estimate of USD 16.99 billion.

South

The South is the largest addressable POC diagnostics market because it combines population scale with high chronic disease burden, extensive hospital networks, rapid suburban development and large rural populations that can benefit from decentralized diagnostic access.

Texas is the most strategically important Southern state. Houston, Dallas–Fort Worth, Austin and San Antonio contain major hospital networks, academic centers, urgent-care chains and ambulatory practices. The state’s large population allows manufacturers to pursue both enterprise health-system contracts and decentralized physician-office placements.

Florida represents another high-value market because of its large older-adult population. Demand is particularly attractive for glucose monitoring, cardiac testing, anticoagulation, respiratory disease diagnosis and urgent-care testing. Seasonal influenza and respiratory demand can generate significant cartridge utilization across retail, senior-care and outpatient environments.

Georgia and North Carolina are increasingly attractive because population growth is occurring alongside expansion of major health systems, biotechnology ecosystems and urban outpatient networks. Atlanta, Charlotte, Raleigh-Durham and surrounding metropolitan markets are strong targets for molecular respiratory diagnostics, diabetes testing and connected POC platforms.

Virginia, Maryland and Tennessee combine sophisticated health systems with substantial ambulatory-care infrastructure. Maryland and Virginia also benefit from proximity to federal health institutions and dense medical-provider networks.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia and Oklahoma represent a different opportunity profile. Chronic disease prevalence and rural access challenges support demand for simple, portable, CLIA-waived platforms, but purchasing budgets and specialist availability can constrain premium system adoption. Manufacturers that combine affordable instrumentation with broad cartridge menus and strong distributor coverage are well positioned.

The South could approach approximately USD 16.20 billion by 2035, corresponding to an implied regional growth rate near 9.9%, and is expected to remain the largest U.S. market.

West

The West is expected to be the fastest-growing region, supported by technology adoption, large health systems, high consumer acceptance of digital health and strong medtech innovation ecosystems. The regional market is estimated at approximately USD 3.91 billion in 2025 and could approach USD 10.70 billion by 2035.

California is the dominant Western state and one of the most important POC diagnostics markets nationally. Its size, hospital concentration, biotechnology sector, venture-capital ecosystem and large urgent-care footprint make it particularly receptive to molecular diagnostics, connected devices and novel home-testing models.

California also plays an outsized role in product development. Visby Medical, for example, is headquartered in San Jose and obtained FDA clearance in May 2026 for its Flu and COVID-19 molecular test, illustrating the region’s role in translating diagnostics innovation into commercial POC products.

Arizona and Nevada offer strong demand growth linked to population expansion and aging demographics. These states are commercially attractive for respiratory testing, diabetes diagnostics and urgent-care platforms.

Washington and Oregon have sophisticated integrated delivery networks and relatively high acceptance of digitally connected care. Procurement decisions frequently emphasize interoperability, standardized workflows and enterprise analytics.

Colorado and Utah offer attractive metropolitan markets with growing hospital systems, ambulatory care and technology-oriented populations. New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii present smaller but strategically relevant opportunities where portable POC systems can mitigate long transportation distances and limited centralized laboratory access.

With an implied CAGR of approximately 10.6%, the West should gain national market share through 2035.

Northeast

The Northeast represented an estimated USD 3.74 billion in 2025 and remains one of the country’s highest-value markets for sophisticated diagnostic technology. It could reach approximately USD 8.65 billion by 2035.

New York is the largest Northeast state market because of its population, academic medical centers, major integrated health systems, emergency-care demand and physician-office base. Large systems can support high testing volumes and enterprise-level POC standardization.

Massachusetts is disproportionately important relative to its population because Boston has one of the country’s densest concentrations of academic medicine, biotechnology and clinical research. Technologies with differentiated evidence frequently obtain early evaluation in such institutions.

Pennsylvania and New Jersey combine large hospital systems with substantial suburban urgent-care, primary-care and ambulatory footprints. These states are attractive for both professional POC systems and consumer-directed testing.

Connecticut, Rhode Island, New Hampshire, Vermont, Maine and Delaware are smaller markets. Rural areas in northern New England create an opportunity for decentralized molecular and chemistry systems, while dense metropolitan corridors favor integrated physician-office and urgent-care testing.

The Northeast is likely to expand at an implied CAGR of approximately 8.7%, slower than the West but with high average technology intensity and strong willingness to evaluate differentiated diagnostic platforms.

Midwest

The Midwest is estimated at approximately USD 3.05 billion in 2025 and could reach approximately USD 6.95 billion by 2035, representing steady growth near 8.6%.

Illinois is the region’s largest concentrated market, led by Chicago’s extensive academic, hospital and outpatient ecosystem. The market supports high-volume acute-care testing alongside decentralized physician-office diagnostics.

Ohio and Michigan have large health-system footprints and significant chronic disease demand. Diabetes, cardiovascular disease and respiratory testing create stable POC utilization across hospitals and outpatient sites.

Minnesota is especially important from a medtech perspective because of its established medical-device ecosystem and sophisticated provider networks. Adoption of connected hospital POC systems and advanced diagnostics is supported by strong institutional experience with medical technology.

Indiana, Wisconsin and Missouri represent dependable mid-sized markets with established hospital networks, while Iowa, Kansas, Nebraska, North Dakota and South Dakota provide a strong use case for portable diagnostics in rural communities.

Rural access is one of the Midwest’s most important commercial themes. A POC platform capable of producing actionable results locally can reduce specimen transportation, patient travel and delayed treatment. For manufacturers, however, success depends on distributor reach, service coverage and the ability to support low-volume sites economically.

Across all four U.S. regions, the national growth opportunity is therefore not simply proportional to population. The fastest-growing commercial territories will be those where chronic disease, outpatient migration, CLIA-waived testing and healthcare labor constraints intersect.

 

Key Market Players

The U.S. Point-of-Care Diagnostics Devices Competitive Landscape is fragmented across several technology domains. A small group of large diagnostics companies controls major installed bases in glucose, immunoassay, molecular testing, blood gases and acute-care diagnostics, while specialized companies compete aggressively in respiratory testing, women’s health, cardiometabolic screening and consumer self-testing.

Important participants include Abbott Laboratories, Roche Diagnostics, Danaher Corporation through Cepheid, QuidelOrtho Corporation, Becton Dickinson, Siemens Healthineers, bioMérieux, Nova Biomedical, Werfen, EKF Diagnostics, Trinity Biotech, OraSure Technologies, Sekisui Diagnostics, Hologic, Thermo Fisher Scientific, ACON Laboratories, Visby Medical, binx health, SD Biosensor/Meridian Bioscience, Sysmex America, ARKRAY USA, Healgen Scientific, PTS Diagnostics and Trividia Health.

Abbott has substantial strength in glucose, rapid infectious-disease testing, cardiometabolic diagnostics and molecular POC systems. Roche possesses a broad diagnostics franchise and strengthened its decentralized strategy by completing the acquisition of LumiraDx’s point-of-care technology in July 2024, adding a multi-assay platform capable of supporting clinical chemistry, immunochemistry, coagulation and molecular applications.

Danaher’s Cepheid business represents a major competitive force in cartridge-based molecular diagnostics. bioMérieux is building a distinct near-patient molecular position through SPOTFIRE. QuidelOrtho competes across rapid immunoassay and molecular testing, while Nova Biomedical and Werfen hold important positions in hospital acute-care diagnostics.

Competitive differentiation over the forecast period will increasingly depend on assay-menu expansion, CLIA waiver, cartridge cost, time to result, analyzer uptime, operator simplicity and connectivity rather than analytical performance alone.

Platform economics will also influence consolidation. Manufacturers capable of placing instruments at low upfront cost and recovering margin through recurring cartridges or strips can establish long-term customer relationships. Consequently, hospital purchasing groups frequently evaluate five- to seven-year reagent commitments rather than isolated instrument purchases.

 

Recent Developments

Recent U.S. market developments show a clear regulatory and competitive move toward multiplex, molecular and CLIA-waived diagnostics.

In 2024, bioMérieux received FDA clearance and CLIA waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel. The system enables near-patient multiplex PCR testing for numerous respiratory and throat pathogens in approximately 15 minutes, extending syndromic molecular testing beyond conventional laboratories.

Also in 2024, Roche completed its acquisition of LumiraDx’s point-of-care technology. The transaction is strategically important because it reflects the value large diagnostics companies place on multi-assay decentralized platforms capable of expanding beyond single-disease testing.

FDA activity in 2024 also included CLIA waiver decisions covering systems such as Nova Biomedical’s StatStrip hospital glucose system, Abbott’s Afinion HbA1c, ACON’s Mission urinalysis system and several molecular infectious-disease platforms, demonstrating that waiver expansion is occurring across multiple POC categories rather than respiratory testing alone.

In May 2026, the FDA cleared Visby Medical’s Flu and COVID-19 Test as an over-the-counter molecular multi-analyte respiratory virus detection test. FDA records subsequently identified it as waived, extending the movement of molecular technology toward simpler and more decentralized workflows.

By July 2026, FDA’s waived-test database also included the ACON Flowflex Plus RSV + Flu A/B + COVID Rapid Test, along with additional respiratory assays from multiple suppliers. The expanding number of multi-analyte respiratory products is intensifying price, distribution and performance competition in a category that was once dominated by separate single-pathogen tests.

The strategic implication is that the next decade of point-of-care diagnostics will involve progressively greater convergence between traditional rapid testing and sophisticated laboratory diagnostics. Molecular testing is becoming simpler, antigen testing is becoming multiplexed, and consumer diagnostics are moving toward professionally meaningful results.

 

Conclusion

The U.S. Point-of-Care Diagnostics Devices Market Size & Share is positioned for aggressive expansion from approximately USD 16.99 billion in 2025 to USD 42.50 billion by 2035, representing an estimated 9.60% CAGR during 2026–2035. Historical market value is estimated to have increased from approximately USD 11.78 billion in 2021 to USD 15.50 billion in 2024 as rapid diagnostic capacity expanded beyond conventional laboratory environments.

Long-term market strength will be supported by diabetes and cardiometabolic disease, recurring respiratory infections, STI and sexual-health testing demand, hospital workflow pressure, growth of urgent care, expanded CLIA-waived testing and increasing consumer acceptance of home diagnostics.

The most attractive technology opportunities are likely to occur in CLIA-waived molecular diagnostics, multiplex infectious-disease testing, connected cardiometabolic platforms, microfluidic analyzers, quantitative biosensors and digitally integrated self-testing. These technologies have the potential to move testing closer to the patient without forcing clinicians to accept major compromises in analytical quality.

Hospitals will remain strategically important because of their testing intensity, but incremental unit placements will increasingly occur in urgent care, physician offices, ambulatory facilities, pharmacies and home settings. The South will remain the largest regional opportunity because of population and disease burden, while the West is expected to deliver the fastest growth through 2035. The Northeast will remain an influential early-adoption market, and the Midwest will provide durable demand with a particularly strong use case for rural decentralized diagnostics.

For companies evaluating the U.S. Point-of-Care Diagnostics Devices Market, the central commercial question is no longer whether diagnostic testing will decentralize. That transition is already underway. The more important questions are which test menus generate enough clinical value to justify their cost, which platforms can obtain and exploit CLIA-waived status, how rapidly molecular testing can approach the simplicity of traditional rapid tests, and which manufacturers can convert analyzer placements into durable consumable revenue.

The companies best positioned through 2035 will be those capable of demonstrating that their systems do more than produce a fast result. They must show that testing at the point of care improves patient throughput, reduces unnecessary treatment, shortens clinical decision time, integrates reliably with health-system data infrastructure and produces an economically defensible result at scale.

 

TABLE OF CONTENT

1. U.S. Point-of-Care Diagnostics Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Point-of-Care Diagnostic Device Manufacturers
1.6.2. Assay, Cartridge, Reagent and Biosensor Suppliers
1.6.3. Hospitals and Integrated Delivery Networks
1.6.4. Physician Offices and Urgent Care Networks
1.6.5. Ambulatory, Specialty and Community Care Facilities
1.6.6. Retail Pharmacies and Home Testing Channels
1.6.7. Group Purchasing Organizations and Diagnostic Distributors
1.6.8. Payers, Regulators, Laboratory Directors and Clinical Decision-Makers

What this section provides: This section defines the market boundary, study scope, methodology, assumptions and stakeholder ecosystem so clients understand how the U.S. point-of-care diagnostics devices market is measured, segmented and validated.

2. U.S. Point-of-Care Diagnostics Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. High-Growth Opportunity Areas
2.10. Fastest-Growing Technology and Application Pockets

What this section provides: This section gives decision-makers a concise view of market size, CAGR, demand direction, technology shifts, competitive intensity and the highest-priority commercial opportunities through 2035.

3. U.S. Point-of-Care Diagnostics Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Burden of Diabetes and Chronic Cardiometabolic Diseases
3.1.2. Growing Demand for Rapid Infectious Disease Diagnosis
3.1.3. Expansion of Decentralized and Near-Patient Testing
3.1.4. Growth of Urgent Care, Physician-Office and Ambulatory Diagnostics
3.1.5. Increasing Adoption of CLIA-Waived Testing Platforms
3.1.6. Hospital Need for Faster Clinical Decision-Making and Patient Throughput
3.1.7. Growth of Home-Based and Consumer-Directed Diagnostic Testing

3.2. Restraints and Their Impact Analysis
3.2.1. Price Pressure on Rapid Diagnostic Tests and Consumables
3.2.2. Reimbursement Variability Across POC Diagnostic Applications
3.2.3. Analytical Accuracy and Clinical Performance Concerns
3.2.4. Operator Training, Quality Control and Compliance Burden
3.2.5. Competition from Central Laboratory Testing
3.2.6. Procurement Pressure from IDNs and Group Purchasing Organizations

3.3. Opportunities and Their Impact Analysis
3.3.1. CLIA-Waived Molecular Diagnostics Expansion
3.3.2. Multiplex Respiratory and Infectious Disease Testing
3.3.3. Rapid Cardiac and Critical-Care Biomarker Testing
3.3.4. Connected Diabetes and Cardiometabolic Testing
3.3.5. Point-of-Care Sexual Health and Women’s Health Diagnostics
3.3.6. Pharmacy-Based and Retail Diagnostic Testing
3.3.7. Digital Connectivity and Remote Result Integration
3.3.8. Rural and Underserved Community Diagnostic Access

3.4. Challenges and Their Impact Analysis
3.4.1. Ensuring Laboratory-Comparable Analytical Performance
3.4.2. Integration with Electronic Health Records and Laboratory Information Systems
3.4.3. Managing High-Volume Device Fleets Across Health Systems
3.4.4. Reagent and Cartridge Supply Reliability
3.4.5. Maintaining Profitability in Competitive Rapid-Test Categories

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Point-of-Care Clinical Workflow Economics Analysis
3.7. Diagnostic Turnaround-Time and Patient Throughput Analysis
3.8. Hospital and Health System Procurement Behavior Analysis
3.9. Installed-Base and Recurring Consumables Business Model Analysis

What this section provides: This section explains the clinical, economic, regulatory, workflow and commercial forces affecting U.S. point-of-care diagnostics demand and enables clients to evaluate upside opportunities alongside adoption and execution risks.

4. U.S. Point-of-Care Diagnostics Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Point-of-Care Diagnostics
4.6. Application & Innovation Landscape
4.7. FDA In Vitro Diagnostic Regulatory Framework Analysis
4.8. CLIA Complexity Classification and Waiver Landscape
4.9. CMS Reimbursement and Coverage Landscape
4.10. CPT and Diagnostic Testing Payment Environment
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Initiatives and Public Health Screening Programs
4.13. Impact of Escalating Geopolitical Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.15. Point-of-Care Device Connectivity and Cybersecurity Considerations

What this section provides: This section gives clients a comprehensive understanding of regulation, CLIA waiver, reimbursement, pricing, supply chain, digital connectivity and procurement factors influencing the U.S. point-of-care diagnostics industry.

5. U.S. Point-of-Care Diagnostics Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Blood Glucose and Diabetes Testing Devices
5.1.2.1. Blood Glucose Meters
5.1.2.2. Professional Glucose Monitoring Systems
5.1.2.3. HbA1c Point-of-Care Analyzers
5.1.2.4. Ketone Testing Devices
5.1.2.5. Test Strips and Dedicated Consumables

5.1.3. Infectious Disease Testing Devices
5.1.3.1. Respiratory Infection Testing Devices
5.1.3.2. Influenza Testing Devices
5.1.3.3. COVID-19 Testing Devices
5.1.3.4. RSV Testing Devices
5.1.3.5. Group A Streptococcus Testing Devices
5.1.3.6. HIV Testing Devices
5.1.3.7. Sexually Transmitted Infection Testing Devices
5.1.3.8. Other Infectious Disease POC Tests

5.1.4. Cardiometabolic and Cardiac Marker Testing Devices
5.1.4.1. Troponin Testing Devices
5.1.4.2. BNP/NT-proBNP Testing Devices
5.1.4.3. Lipid and Cholesterol Testing Devices
5.1.4.4. C-Reactive Protein Testing Devices
5.1.4.5. Other Cardiometabolic Biomarker Devices

5.1.5. Coagulation and Critical-Care Testing Devices
5.1.5.1. PT/INR Testing Devices
5.1.5.2. Blood Gas Analyzers
5.1.5.3. Electrolyte Testing Devices
5.1.5.4. Lactate Testing Devices
5.1.5.5. Critical-Care Chemistry Devices

5.1.6. Pregnancy, Fertility and Women’s Health Testing Devices
5.1.6.1. Pregnancy Testing Devices
5.1.6.2. Fertility and Ovulation Testing Devices
5.1.6.3. Vaginitis Testing Devices
5.1.6.4. Women’s Sexual Health Diagnostics

5.1.7. Hematology, Urinalysis and Other Point-of-Care Devices
5.1.7.1. Hemoglobin and Hematocrit Testing Devices
5.1.7.2. Compact Hematology Analyzers
5.1.7.3. Urinalysis Systems
5.1.7.4. Renal Function Testing Devices
5.1.7.5. Multi-Analyte Point-of-Care Systems

What this section provides: This section identifies the diagnostic device and consumable categories generating the largest revenue pools and highlights product groups expected to deliver the strongest value growth through 2035.

6. U.S. Point-of-Care Diagnostics Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)

6.1.2. Infectious Disease Diagnosis
6.1.2.1. Respiratory Infection Diagnosis
6.1.2.2. Streptococcal Infection Diagnosis
6.1.2.3. HIV and STI Diagnosis
6.1.2.4. Other Communicable Disease Diagnosis

6.1.3. Diabetes and Endocrine Management
6.1.3.1. Routine Glucose Monitoring
6.1.3.2. HbA1c Monitoring
6.1.3.3. Acute Glycemic Assessment
6.1.3.4. Diabetes Screening

6.1.4. Cardiovascular and Critical-Care Diagnosis
6.1.4.1. Acute Myocardial Injury Assessment
6.1.4.2. Heart Failure Assessment
6.1.4.3. Blood Gas and Acid-Base Assessment
6.1.4.4. Coagulation Monitoring
6.1.4.5. Sepsis and Critical-Care Assessment

6.1.5. Women’s Health, Pregnancy and Sexual Health
6.1.5.1. Pregnancy Detection
6.1.5.2. Fertility Monitoring
6.1.5.3. Vaginal Infection Diagnosis
6.1.5.4. Sexual Health Screening

6.1.6. Renal, Urinary and General Screening Applications
6.1.6.1. Urinary Tract Assessment
6.1.6.2. Renal Function Assessment
6.1.6.3. Hemoglobin Screening
6.1.6.4. General Wellness and Community Screening

What this section provides: This section explains demand by clinical use case and enables clients to prioritize applications where rapid turnaround, treatment initiation, patient throughput and decentralized testing provide the strongest economic value.

7. U.S. Point-of-Care Diagnostics Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)

7.1.2. Hospitals and Health Systems
7.1.2.1. Emergency Departments
7.1.2.2. Intensive Care Units
7.1.2.3. Inpatient Nursing Units
7.1.2.4. Operating Rooms and Perioperative Care
7.1.2.5. Labor and Delivery Units

7.1.3. Physician Offices and Urgent Care Centers
7.1.3.1. Primary Care Practices
7.1.3.2. Pediatric Practices
7.1.3.3. Urgent Care Networks
7.1.3.4. Family Medicine Practices

7.1.4. Ambulatory, Emergency and Specialty Care Facilities
7.1.4.1. Ambulatory Surgery Centers
7.1.4.2. Freestanding Emergency Centers
7.1.4.3. Anticoagulation Clinics
7.1.4.4. Dialysis and Renal Care Centers
7.1.4.5. Specialty Physician Practices

7.1.5. Pharmacies, Retail Clinics and Community Testing Sites
7.1.5.1. Retail Pharmacy Chains
7.1.5.2. In-Store Health Clinics
7.1.5.3. Community Health Centers
7.1.5.4. Public Health Testing Sites

7.1.6. Home Care and Self-Testing
7.1.6.1. Consumer OTC Diagnostic Testing
7.1.6.2. Home Chronic Disease Testing
7.1.6.3. Home Infectious Disease Testing
7.1.6.4. Digitally Connected Home Diagnostics

What this section provides: This section determines which U.S. care settings generate the strongest analyzer placements, recurring test consumption and future decentralized-testing demand.

8. U.S. Point-of-Care Diagnostics Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)

8.1.2. Lateral Flow Assays
8.1.2.1. Visual Lateral Flow Tests
8.1.2.2. Reader-Based Lateral Flow Tests
8.1.2.3. Multiplex Lateral Flow Assays

8.1.3. Molecular Diagnostic Technologies
8.1.3.1. Polymerase Chain Reaction
8.1.3.2. Isothermal Nucleic Acid Amplification
8.1.3.3. Cartridge-Based Molecular Diagnostics
8.1.3.4. Multiplex Molecular Platforms

8.1.4. Biosensor and Electrochemical Technologies
8.1.4.1. Electrochemical Biosensors
8.1.4.2. Optical Biosensors
8.1.4.3. Enzyme-Based Biosensors
8.1.4.4. Multi-Analyte Sensor Platforms

8.1.5. Immunoassay and Fluorescence-Based Technologies
8.1.5.1. Fluorescence Immunoassays
8.1.5.2. Chemiluminescence-Based POC Systems
8.1.5.3. Quantitative Immunoassay Readers

8.1.6. Microfluidics and Integrated Diagnostic Technologies
8.1.6.1. Lab-on-a-Chip Systems
8.1.6.2. Microfluidic Cartridge Platforms
8.1.6.3. Sample-to-Answer Systems
8.1.6.4. Digitally Connected Diagnostic Platforms

What this section provides: This section evaluates the technology platforms reshaping point-of-care diagnostics and identifies technologies positioned to gain share through faster testing, multiplexing, automation and improved analytical performance.

9. U.S. Point-of-Care Diagnostics Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)

9.1.2. Direct Hospital and Health System Procurement
9.1.2.1. Individual Hospital Contracts
9.1.2.2. Multi-Hospital Health System Contracts
9.1.2.3. Reagent Rental and Instrument Placement Agreements

9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.3.1. Enterprise Platform Standardization
9.1.3.2. Multi-Year Reagent Commitments
9.1.3.3. Connected Device Fleet Procurement

9.1.4. Group Purchasing Organization Contracts
9.1.4.1. National GPO Contracts
9.1.4.2. Regional GPO Contracts
9.1.4.3. Aggregated Purchasing Arrangements

9.1.5. Distributor and Specialty Diagnostic Supplier Sales
9.1.5.1. National Diagnostic Distributors
9.1.5.2. Regional Medical Distributors
9.1.5.3. Physician-Office Laboratory Suppliers

9.1.6. Retail, E-Commerce and Direct-to-Consumer Channels
9.1.6.1. Retail Pharmacies
9.1.6.2. Online Retail
9.1.6.3. Manufacturer Direct-to-Consumer Sales
9.1.6.4. Home Diagnostic Distribution Channels

What this section provides: This section explains how point-of-care diagnostic devices and recurring tests are purchased across U.S. healthcare channels, including IDN standardization, GPO influence, reagent contracts, distributor economics and direct-to-consumer models.

10. U.S. Point-of-Care Diagnostics Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Point-of-Care Testing Volume Analysis
10.1.4. Regional Hospital, Urgent Care and Physician-Office Infrastructure Analysis
10.1.5. Regional CLIA-Waived Testing Site Analysis
10.1.6. Regional Chronic Disease and Infectious Disease Demand Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers and Diagnostic Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers and Diagnostic Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers and Diagnostic Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers and Diagnostic Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers comprehensive regional and state-level analysis, allowing clients to identify priority U.S. markets, CLIA-waived testing hotspots, hospital and urgent-care clusters, rural diagnostic opportunities and state-level commercial expansion potential.

11. U.S. Point-of-Care Diagnostics Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players

11.3. Company Profiles

11.3.1. Abbott Laboratories
11.3.2. Roche Diagnostics
11.3.3. Danaher Corporation / Cepheid
11.3.4. QuidelOrtho Corporation
11.3.5. Becton, Dickinson and Company
11.3.6. Siemens Healthineers
11.3.7. bioMérieux
11.3.8. Nova Biomedical
11.3.9. Werfen
11.3.10. EKF Diagnostics Holdings
11.3.11. Trinity Biotech
11.3.12. OraSure Technologies
11.3.13. Sekisui Diagnostics
11.3.14. Hologic
11.3.15. Thermo Fisher Scientific
11.3.16. ACON Laboratories
11.3.17. Visby Medical
11.3.18. binx health
11.3.19. SD Biosensor / Meridian Bioscience
11.3.20. Sysmex America
11.3.21. ARKRAY USA
11.3.22. Healgen Scientific
11.3.23. PTS Diagnostics
11.3.24. Trividia Health

11.4. Competitive Benchmarking by Diagnostic Portfolio
11.4.1. Infectious Disease Testing Portfolio
11.4.2. Diabetes and Cardiometabolic Portfolio
11.4.3. Molecular POC Diagnostics Portfolio
11.4.4. Critical-Care and Blood Gas Portfolio
11.4.5. Home and Self-Testing Portfolio

11.5. Competitive Benchmarking by Strategic Capability
11.5.1. U.S. Installed Base
11.5.2. CLIA-Waived Assay Menu
11.5.3. Test Turnaround Time
11.5.4. Connectivity and Informatics Capability
11.5.5. Consumables and Recurring Revenue Exposure
11.5.6. Distribution Reach
11.5.7. FDA Regulatory Pipeline

Note: Each company profile will include company overview, U.S. point-of-care diagnostics portfolio, market strategy, financial positioning, installed-base strategy, assay pipeline, FDA and CLIA developments, partnerships, acquisitions and recent developments.

What this section provides: This section provides competitor benchmarking, market-share visibility, assay and platform positioning, regulatory pipeline intelligence and strategic assessment of the leading companies competing in U.S. point-of-care diagnostics.

12. U.S. Point-of-Care Diagnostics Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. CLIA-Waived Molecular Diagnostics
12.2.2. Multiplex Respiratory Diagnostic Platforms
12.2.3. Sample-to-Answer Molecular Systems
12.2.4. Microfluidic Lab-on-a-Chip Platforms
12.2.5. Advanced Biosensors
12.2.6. AI-Assisted Diagnostic Interpretation
12.2.7. Smartphone-Connected Point-of-Care Diagnostics
12.2.8. Digitally Connected Home Diagnostics

12.3. Emerging Business Trends
12.3.1. Decentralization of Clinical Diagnostics
12.3.2. Shift from Single-Test to Multi-Assay Platforms
12.3.3. Reagent-Rental and Consumables-Led Business Models
12.3.4. Retail Pharmacy Diagnostic Expansion
12.3.5. Growth of Direct-to-Consumer Diagnostics
12.3.6. Consolidation of Point-of-Care Diagnostic Platforms

12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. High-Growth Application Opportunity Matrix
12.7. Technology Adoption Roadmap, 2026–2035
12.8. Regulatory and Reimbursement Evolution Outlook

What this section provides: This section prepares clients for emerging diagnostic technologies, changing care locations, regulatory evolution, platform consolidation and investment opportunities likely to reshape the market through 2035.

13. U.S. Point-of-Care Diagnostics Devices Market: Strategic Recommendations

13.1. Recommendations for Point-of-Care Diagnostic Manufacturers
13.2. Recommendations for Hospitals and Integrated Delivery Networks
13.3. Recommendations for Physician Offices and Urgent Care Operators
13.4. Recommendations for Retail Pharmacies and Community Testing Providers
13.5. Recommendations for Investors and Private Equity Firms
13.6. Recommendations for Distributors and Channel Partners
13.7. Recommendations for New Entrants and Diagnostic Startups
13.8. Go-to-Market Strategy Considerations
13.9. CLIA-Waiver and Regulatory Commercialization Strategy
13.10. Product Positioning and Assay Menu Expansion Guidance
13.11. Installed-Base and Consumables Revenue Strategy
13.12. Pricing and Contracting Strategy
13.13. U.S. State-Level Commercial Prioritization Strategy

What this section provides: This section converts market intelligence into actionable recommendations for platform development, assay expansion, commercialization, procurement engagement, geographic expansion, investment and long-term competitive differentiation.

14. U.S. Point-of-Care Diagnostics Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Legal Disclaimer
14.5. Third-Party Data Disclaimer
14.6. Market Definition and Product Inclusion Limitation
14.7. Regulatory and Reimbursement Information Limitation

What this section provides: This section clarifies the report’s methodological, forecasting, regulatory, legal and data-use limitations and establishes the appropriate boundaries for interpretation of the market estimates and strategic analysis.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Point-of-Care Diagnostics Devices Market: Market Definition and Scope
TABLE 3: U.S. Point-of-Care Diagnostics Devices Market: Research Methodology Framework
TABLE 4: U.S. Point-of-Care Diagnostics Devices Market: Key Assumptions
TABLE 5: U.S. Point-of-Care Diagnostics Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Point-of-Care Diagnostics Devices Market: Stakeholder Analysis
TABLE 7: U.S. Point-of-Care Diagnostics Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Point-of-Care Diagnostics Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Point-of-Care Diagnostics Devices Market: Market Attractiveness Index
TABLE 10: U.S. Point-of-Care Diagnostics Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Point-of-Care Diagnostics Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Point-of-Care Diagnostics Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Point-of-Care Diagnostics Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Point-of-Care Diagnostics Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Point-of-Care Diagnostics Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Point-of-Care Diagnostics Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Point-of-Care Diagnostics Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Point-of-Care Diagnostics Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Point-of-Care Diagnostics Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Point-of-Care Diagnostics Devices Market: Diagnostic Turnaround-Time and Patient Throughput Matrix
TABLE 21: U.S. Point-of-Care Diagnostics Devices Market: Hospital and Health System Procurement Behavior Matrix
TABLE 22: U.S. Point-of-Care Diagnostics Devices Market: Installed-Base and Recurring Consumables Business Model
TABLE 23: U.S. Point-of-Care Diagnostics Devices Market: PESTEL Analysis
TABLE 24: U.S. Point-of-Care Diagnostics Devices Market: Porter’s Five Forces Analysis
TABLE 25: U.S. Point-of-Care Diagnostics Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 26: U.S. Point-of-Care Diagnostics Devices Market: Value Chain Analysis
TABLE 27: U.S. Point-of-Care Diagnostics Devices Market: Supply Chain Analysis
TABLE 28: U.S. Point-of-Care Diagnostics Devices Market: Digitalization and Connected POC Diagnostics Impact
TABLE 29: U.S. Point-of-Care Diagnostics Devices Market: Application & Innovation Landscape
TABLE 30: U.S. Point-of-Care Diagnostics Devices Market: FDA IVD Regulatory Framework Analysis
TABLE 31: U.S. Point-of-Care Diagnostics Devices Market: CLIA Complexity and Waiver Landscape
TABLE 32: U.S. Point-of-Care Diagnostics Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Point-of-Care Diagnostics Devices Market: CPT and Diagnostic Testing Payment Environment
TABLE 34: U.S. Point-of-Care Diagnostics Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 35: U.S. Point-of-Care Diagnostics Devices Market: Government Initiatives and Public Health Programs
TABLE 36: U.S. Point-of-Care Diagnostics Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 37: U.S. Point-of-Care Diagnostics Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 38: U.S. Point-of-Care Diagnostics Devices Market: Connectivity and Cybersecurity Considerations
TABLE 39: U.S. Point-of-Care Diagnostics Devices Market: Product Type Snapshot, 2025
TABLE 40: Segment Dashboard; Definition and Scope, by Product Type
TABLE 41: U.S. Point-of-Care Diagnostics Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 42: U.S. Point-of-Care Diagnostics Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 43: U.S. Point-of-Care Diagnostics Devices Market: Blood Glucose and Diabetes Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Point-of-Care Diagnostics Devices Market: Infectious Disease Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Point-of-Care Diagnostics Devices Market: Cardiometabolic and Cardiac Marker Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Point-of-Care Diagnostics Devices Market: Coagulation and Critical-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Point-of-Care Diagnostics Devices Market: Pregnancy, Fertility and Women’s Health Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Point-of-Care Diagnostics Devices Market: Hematology, Urinalysis and Other POC Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Point-of-Care Diagnostics Devices Market: Application Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Application
TABLE 51: U.S. Point-of-Care Diagnostics Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 52: U.S. Point-of-Care Diagnostics Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 53: U.S. Point-of-Care Diagnostics Devices Market: Infectious Disease Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Point-of-Care Diagnostics Devices Market: Diabetes and Endocrine Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Point-of-Care Diagnostics Devices Market: Cardiovascular and Critical-Care Diagnosis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Point-of-Care Diagnostics Devices Market: Women’s Health, Pregnancy and Sexual Health Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Point-of-Care Diagnostics Devices Market: Renal, Urinary and General Screening Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Point-of-Care Diagnostics Devices Market: End User Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by End User
TABLE 60: U.S. Point-of-Care Diagnostics Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 61: U.S. Point-of-Care Diagnostics Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 62: U.S. Point-of-Care Diagnostics Devices Market: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Point-of-Care Diagnostics Devices Market: Physician Offices and Urgent Care Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Point-of-Care Diagnostics Devices Market: Ambulatory, Emergency and Specialty Care Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Point-of-Care Diagnostics Devices Market: Pharmacies, Retail Clinics and Community Testing Sites Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Point-of-Care Diagnostics Devices Market: Home Care and Self-Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Point-of-Care Diagnostics Devices Market: Technology Type Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 69: U.S. Point-of-Care Diagnostics Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 70: U.S. Point-of-Care Diagnostics Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 71: U.S. Point-of-Care Diagnostics Devices Market: Lateral Flow Assays Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Point-of-Care Diagnostics Devices Market: Molecular Diagnostic Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Point-of-Care Diagnostics Devices Market: Biosensor and Electrochemical Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Point-of-Care Diagnostics Devices Market: Immunoassay and Fluorescence-Based Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Point-of-Care Diagnostics Devices Market: Microfluidics and Integrated Diagnostic Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Point-of-Care Diagnostics Devices Market: Procurement Channel Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 78: U.S. Point-of-Care Diagnostics Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 79: U.S. Point-of-Care Diagnostics Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 80: U.S. Point-of-Care Diagnostics Devices Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Point-of-Care Diagnostics Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Point-of-Care Diagnostics Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Point-of-Care Diagnostics Devices Market: Distributor and Specialty Diagnostic Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Point-of-Care Diagnostics Devices Market: Retail, E-Commerce and Direct-to-Consumer Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Point-of-Care Diagnostics Devices Market: Regional Snapshot, 2025
TABLE 86: Segment Dashboard; Definition and Scope, by Geography
TABLE 87: U.S. Point-of-Care Diagnostics Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 88: U.S. Point-of-Care Diagnostics Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 89: West Region U.S. Point-of-Care Diagnostics Devices Market: Regional Overview and Trends
TABLE 90: West Region U.S. Point-of-Care Diagnostics Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 91: West Region U.S. Point-of-Care Diagnostics Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Point-of-Care Diagnostics Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Point-of-Care Diagnostics Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Point-of-Care Diagnostics Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Point-of-Care Diagnostics Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. Point-of-Care Diagnostics Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 97: California Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Washington Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Arizona Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Colorado Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Oregon Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Utah Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Nevada Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: New Mexico Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Idaho Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Montana Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Wyoming Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Alaska Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Hawaii Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Northeast Region U.S. Point-of-Care Diagnostics Devices Market: Regional Overview and Trends
TABLE 111: Northeast Region U.S. Point-of-Care Diagnostics Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 112: Northeast Region U.S. Point-of-Care Diagnostics Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Point-of-Care Diagnostics Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Point-of-Care Diagnostics Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Point-of-Care Diagnostics Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Point-of-Care Diagnostics Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 117: Northeast Region U.S. Point-of-Care Diagnostics Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 118: New York Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Massachusetts Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: New Jersey Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Pennsylvania Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Connecticut Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Maine Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Vermont Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: New Hampshire Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Rhode Island Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Delaware Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: South Region U.S. Point-of-Care Diagnostics Devices Market: Regional Overview and Trends
TABLE 129: South Region U.S. Point-of-Care Diagnostics Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 130: South Region U.S. Point-of-Care Diagnostics Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Point-of-Care Diagnostics Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Point-of-Care Diagnostics Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Point-of-Care Diagnostics Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. Point-of-Care Diagnostics Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 135: South Region U.S. Point-of-Care Diagnostics Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 136: Texas Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Florida Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Georgia Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: North Carolina Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Tennessee Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: South Carolina Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Alabama Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Mississippi Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Louisiana Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Arkansas Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Kentucky Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Oklahoma Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Virginia Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Maryland Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: West Virginia Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Midwest Region U.S. Point-of-Care Diagnostics Devices Market: Regional Overview and Trends
TABLE 152: Midwest Region U.S. Point-of-Care Diagnostics Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 153: Midwest Region U.S. Point-of-Care Diagnostics Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Point-of-Care Diagnostics Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Point-of-Care Diagnostics Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Point-of-Care Diagnostics Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Point-of-Care Diagnostics Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 158: Midwest Region U.S. Point-of-Care Diagnostics Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 159: Illinois Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Ohio Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Michigan Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Minnesota Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Indiana Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Wisconsin Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Missouri Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Iowa Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Kansas Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Nebraska Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: North Dakota Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: South Dakota Point-of-Care Diagnostics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: U.S. Point-of-Care Diagnostics Devices Market: Competitive Landscape Snapshot, 2025
TABLE 172: U.S. Point-of-Care Diagnostics Devices Market: Key Company Market Share Analysis, 2025
TABLE 173: U.S. Point-of-Care Diagnostics Devices Market: Company Positioning Matrix
TABLE 174: U.S. Point-of-Care Diagnostics Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 175: U.S. Point-of-Care Diagnostics Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 176: Abbott Laboratories: Company Profile
TABLE 177: Roche Diagnostics: Company Profile
TABLE 178: Danaher Corporation / Cepheid: Company Profile
TABLE 179: QuidelOrtho Corporation: Company Profile
TABLE 180: Becton, Dickinson and Company: Company Profile
TABLE 181: Siemens Healthineers: Company Profile
TABLE 182: bioMérieux: Company Profile
TABLE 183: Nova Biomedical: Company Profile
TABLE 184: Werfen: Company Profile
TABLE 185: EKF Diagnostics Holdings: Company Profile
TABLE 186: Trinity Biotech: Company Profile
TABLE 187: OraSure Technologies: Company Profile
TABLE 188: Sekisui Diagnostics: Company Profile
TABLE 189: Hologic: Company Profile
TABLE 190: Thermo Fisher Scientific: Company Profile
TABLE 191: ACON Laboratories: Company Profile
TABLE 192: Visby Medical: Company Profile
TABLE 193: binx health: Company Profile
TABLE 194: SD Biosensor / Meridian Bioscience: Company Profile
TABLE 195: Sysmex America: Company Profile
TABLE 196: ARKRAY USA: Company Profile
TABLE 197: Healgen Scientific: Company Profile
TABLE 198: PTS Diagnostics: Company Profile
TABLE 199: Trividia Health: Company Profile
TABLE 200: U.S. Point-of-Care Diagnostics Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 201: U.S. Point-of-Care Diagnostics Devices Market: Disruptive Technologies Impact Matrix
TABLE 202: U.S. Point-of-Care Diagnostics Devices Market: Emerging Business Trends
TABLE 203: U.S. Point-of-Care Diagnostics Devices Market: Business Opportunities for Startups and Existing Players
TABLE 204: U.S. Point-of-Care Diagnostics Devices Market: Investment Prioritization Matrix
TABLE 205: U.S. Point-of-Care Diagnostics Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 206: U.S. Point-of-Care Diagnostics Devices Market: Strategic Recommendations for Diagnostic Manufacturers
TABLE 207: U.S. Point-of-Care Diagnostics Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 208: U.S. Point-of-Care Diagnostics Devices Market: Strategic Recommendations for Urgent Care and Physician Offices
TABLE 209: U.S. Point-of-Care Diagnostics Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 210: U.S. Point-of-Care Diagnostics Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 211: U.S. Point-of-Care Diagnostics Devices Market: Go-to-Market Strategy Considerations
TABLE 212: U.S. Point-of-Care Diagnostics Devices Market: Product Positioning and Assay Menu Expansion Guidance
TABLE 213: U.S. Point-of-Care Diagnostics Devices Market: Scope Limitation
TABLE 214: U.S. Point-of-Care Diagnostics Devices Market: Data Use Limitation
TABLE 215: U.S. Point-of-Care Diagnostics Devices Market: Forecasting Limitation
TABLE 216: U.S. Point-of-Care Diagnostics Devices Market: Legal Disclaimer
TABLE 217: U.S. Point-of-Care Diagnostics Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Point-of-Care Diagnostics Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Hospital and Health System Procurement Decision Framework
FIGURE 12: U.S. Point-of-Care Diagnostics Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 13: U.S. Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 14: U.S. Point-of-Care Diagnostics Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 15: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: Blood Glucose and Diabetes Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Infectious Disease Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Cardiometabolic and Cardiac Marker Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Coagulation and Critical-Care Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Pregnancy, Fertility and Women’s Health Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Hematology, Urinalysis and Other POC Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Infectious Disease Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Diabetes and Endocrine Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Cardiovascular and Critical-Care Diagnosis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Women’s Health, Pregnancy and Sexual Health Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Renal, Urinary and General Screening Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 31: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Hospitals and Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Physician Offices and Urgent Care Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Ambulatory, Emergency and Specialty Care Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Pharmacies, Retail Clinics and Community Testing Sites Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Home Care and Self-Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Lateral Flow Assays Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Molecular Diagnostic Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Biosensor and Electrochemical Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Immunoassay and Fluorescence-Based Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Microfluidics and Integrated Diagnostic Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Distributor and Specialty Diagnostic Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Retail, E-Commerce and Direct-to-Consumer Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 52: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: West Region U.S. Point-of-Care Diagnostics Devices Market Share and Leading Players, 2025
FIGURE 54: West Region Market Share Analysis by State, 2025
FIGURE 55: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: California Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Washington Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Arizona Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Colorado Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Oregon Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Utah Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Nevada Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: New Mexico Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Idaho Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Montana Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Wyoming Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Alaska Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Hawaii Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Northeast Region U.S. Point-of-Care Diagnostics Devices Market Share and Leading Players, 2025
FIGURE 70: Northeast Region Market Share Analysis by State, 2025
FIGURE 71: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: New York Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Massachusetts Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: New Jersey Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Pennsylvania Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Connecticut Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Maine Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Vermont Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: New Hampshire Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Rhode Island Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Delaware Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: South Region U.S. Point-of-Care Diagnostics Devices Market Share and Leading Players, 2025
FIGURE 83: South Region Market Share Analysis by State, 2025
FIGURE 84: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Texas Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Florida Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Georgia Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: North Carolina Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Tennessee Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: South Carolina Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Alabama Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Mississippi Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Louisiana Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Arkansas Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Kentucky Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Oklahoma Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Virginia Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Maryland Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: West Virginia Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Midwest Region U.S. Point-of-Care Diagnostics Devices Market Share and Leading Players, 2025
FIGURE 101: Midwest Region Market Share Analysis by State, 2025
FIGURE 102: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Illinois Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Ohio Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Michigan Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Minnesota Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Indiana Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Wisconsin Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Missouri Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Iowa Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Kansas Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Nebraska Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: North Dakota Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: South Dakota Point-of-Care Diagnostics Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 116: Company Positioning Matrix
FIGURE 117: Key Player Product Portfolio Benchmarking
FIGURE 118: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 119: Point-of-Care Diagnostics Innovation Roadmap
FIGURE 120: CLIA-Waived Molecular Diagnostics Adoption Roadmap
FIGURE 121: Multiplex Respiratory Diagnostics Opportunity Map
FIGURE 122: Connected and Home Diagnostics Growth Roadmap
FIGURE 123: Future Market Scenario Analysis, 2026–2035
FIGURE 124: Disruptive Technologies Impact Matrix
FIGURE 125: Emerging Business Trends Matrix
FIGURE 126: Investment Prioritization Matrix
FIGURE 127: Strategic Growth Roadmap for U.S. Point-of-Care Diagnostics Companies
FIGURE 128: Go-to-Market Strategy Framework
FIGURE 129: Product Positioning and Assay Menu Expansion Framework
FIGURE 130: Report Scope and Disclaimer Framework